Adhera Therapeutics

Adhera Therapeutics is a clinical-stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated development pathways. Adhera's legacy assets include CEQ508, an orally administered small interfering RNA (siRNA) targeting β-catenin for the suppression of polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis (FAP).